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SUMMARY
In clinical rheumatology, the diagnosis of Chlamydia reactive arthritis is difficult because an incomplete form of the disease can
closely resemble an undifferentiated seronegative mono/oligoarthritis. We investigated whether measuring specific isotypes of
anti-Chlamydia antibodies in serum can improve the diagnosis, by comparing such antibody concentrations in the serum of
patients with well-defined disease, i.e. Chlamydia trachomatis sexually acquired reactive arthritis (CT-SARA), with other
arthritides. Antibody levels were determined by enzyme-linked immunosorbent assay (ELISA). When considering two different
isotypes and their combination, the best sensitivity (63%) was obtained for IgM and/or IgA results with a specificity of 81%.
The patients with CT-SARA and SARA had the highest levels of antibodies of all isotypes tested. It is concluded that, in our
experimental conditions, only very high values of specific isotypes could indicate a diagnosis of Chlamydia reactive arthritis.
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CHLAMYDIA has been shown to induce arthritis in man
mostly after sexually acquired genitourinary infection
[1]. Several studies [2-6] have shown that an acute
Chlamydia trachomatis (CT) infection was present in
36-69% of patients, immediately before the onset of
sexually acquired reactive arthritis (SARA), even in
the absence of clinical symptoms of urethritis. An
incomplete form of reactive arthritis without a history
of an initial infectious event can closely resemble
an undifferentiated seronegative mono/oligoarthritis.
Kingsley and Sieper [7] reported that reactive arthritis
with a subclinical rather than a clinical triggering
infection is common, but is not often recognized as
such. It is well known that some chlamydial infections
in humans can be inapparent [8] and CT has been
found in urogenital samples of patients without
appropriate symptoms and mono/oligoarthritis [9-11].
Chlamydia pneumoniae may also trigger undifferenti-
ated oligoarthritis [12].
In current practice, the diagnosis of Chlamydia
reactive arthritis is difficult and based on clinical
suspicion, the demonstration of organisms in genito-
urinary specimens and/or the detection of serum
antibodies. The role of serological testing in diagnosis
remains controversial because antibodies against
Chlamydia are frequent in the general population.
Epidemiological studies have revealed a prevalence of
positive antibody tests for this organism in ~ 5 % of the
normal population [13, 14] and in 10-45% of patients
attending sexually transmitted disease clinics in
Western Europe and North America [8].
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Wollenhaupt et al. [15] found that the determination
of C/i/a/ny^/a-specific serum antibodies of the IgA class
may yield further diagnostic information in IgG-pos-
itive patients with suspected chlamydial-induced
arthritis. However, Sieper et al. [16] determined the
value of specific antibody detection in the diagnosis
of reactive arthritis and concluded that no test had a
significant positive predictive value (PPV) for reactive
arthritis in the general population and, even in the
rheumatology clinic, the PPV was low.
We therefore investigated whether measuring specific
isotypes of anti-Chlamydia antibodies in serum could
improve the diagnosis of Chlamydia reactive' arthritis
by comparing such antibody concentrations in the
serum of patients with well-defined disease, i.e.
CT-SARA, with other arthritides. We have determined
the concentrations of serum IgG, IgM and IgA
antibodies against Chlamydia by an enzyme-linked
immunosorbent assay (ELISA) method in 103
patients with different forms of arthritis (30 having a
well-characterized CT-SARA), and have compared the
results obtained for one, two or three isotypes in
CT-SARA with those in other forms of arthritis and in
healthy blood donors.
PATIENTS AND METHODS
Patients
Serum samples came from our serum collection and
have been kept for various times at — 70°C. The
diagnosis was taken from the chart at the time of
sample collection. All the patients were questioned
about possible genitourinary infection (urethritis,
dysuria, discharge?).
Patients were divided into the following groups. 1.
CT-SARA (/i = 30): asymmetrical mono/oligoarthritis
with urethritis and evidence of C. trachomatis infection
[five had a positive urethral/endocervical Chlamydia
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antigen detection by direct immunofluorescence (IF),
24 had a positive urethral/endocervical Chlamydia
culture and had been included in a study on reactive
arthritis [11], one had a positive urethral Chlamydia
DNA amplification with the Amplicor test of Roche
Diagnostic Systems Inc. (Branchburg, NJ)]; median age
(yr): 25, range: 18-58; 20% were female patients;
HLA-B27: 12 positive, 13 negative patients, five not
determined. 2. SARA (n = 23): asymmetrical mono/
oligoarthritis with urethritis, but without proof or
evidence for CT infection (15 had a negative
urethral/endocervical Chlamydia detection, for eight
patients the detection was not performed); median age
(yr): 36, range: 19-62; 13% were female patients;
HLA-B27: seven positive, eight negative patients,
eight not determined. 3. Undifferentiated rheumatoid
factor-negative mono/oligoarthritis (n = 56): 1-4
joints, asymmetrical, mainly lower extremities; absence
of evidence for another denned rheumatic disease;
median age (yr): 40, range: 16-77; 46% were female
patients; HLA-B27: six positive, 25 negative patients,
25 not determined. 4. Rheumatoid factor-positive
rheumatoid arthritis (RA) (n = 37): median age (yr):
63, range: 24-83; 70% were female patients. 5. Crystal-
induced arthritis (n = 17): gout (8), chondrocalcinosis
(9); median age (yr): 51, range: 33-88; 24% were
female patients. 6. Mechanical arthropathies (n = 19):
osteoarthritis (9), femoropatellar chondropathies (3),
post-traumatic arthropathies (3), meniscus lesion (3),
fracture (1); median age (yr): 58, range: 22-80; 63%
were female patients.
The urethral/endocervical Chlamydia detection was
not performed for the negative disease groups (4, 5
and 6) and was presumed to be negative.
The healthy control group was composed of 100
blood donors; median age (yr): 44, range: 22-68; 37%
were female individuals.
Materials
Flat-well microtitre plates (Immunoplate I, catalogue
no. 439454) were purchased from Nunc (Life Tech-
nologies, Basel, Switzerland), CT LGV-1 + Chlamydia
psittaci 6BC antigen preparation from Virion (Cham,
Switzerland), fetal calf serum (FCS) from Gibco (Life
Technologies, Basel, Switzerland) and F(ab02 fragment
of polyclonal goat IgG anti-human IgG, IgM or IgA
from Cappel (Embrach, Switzerland).
Measurements of anti-Chlamydia antibodies by ELISA
The strains used for the Chlamydia antigen
preparation were CT LGV-1 and C. psittaci 6BC, both
obtained from the American Type Culture Collection.
They were grown in the Vero cell line, disrupted by
homogenization and an elementary body-enriched
fraction separated by sucrose density-gradient
differential centrifugation. The control antigen was
prepared in parallel using non-infected cells. Flat-well
microtitre plates were used as the solid phase and
'coated' overnight at 4°C with 100 fi I/well of Chlamydia
antigen or control antigen protein (1.5/ig/ml),
dissolved in carbonate 'coating' buffer (pH 9.6). FCS
(1%) was used to saturate the microplates after
'coating' (100/iI/well for l h at room temperature).
Dilutions (usually 1/20, 1/40, 1/80, more if necessary)
of the same sample in phosphate-buffered saline (PBS)
with 0.05% Tween 20 were tested for Chlamydia
antibodies and for anticellular antibodies (100 /il/well
for 2 h at room temperature). Antibody was detected
with alkaline phosphatase-labelled (conjugation
according to Voller et al. [17]) Ffcb^ fragment of
polyclonal goat IgG anti-human IgG (Fc specific), IgM
(ji chain specific) or IgA (a chain specific) (100 /il/well
for 2 h at room temperature). The working dilutions
of the alkaline phosphatase-labelled antibodies
were determined after calibration with the previous
homemade preparation and were usually 1/600.
Substrate (100 /il/well of 1 mg/ml p-nitrophenyl
phosphate in 10% diethanolamine) was added for 1 h
at room temperature. The colour development was
stopped by addition of 25 /il/well of 3 M NaOH.
The optical density (OD) value obtained for the
control antigen was subtracted from the OD value
obtained for chlamydial antigen. A plot of the OD
versus sample dilutions for high-positive sera used as
standard and different patient sera showed parallel
curves. Antibodies were quantified by comparing the
OD at 410 nm of three serial 2-fold dilutions with
standard curves using a Dynatech MR 5000 Microplate
reader linked to a Macintosh computer equipped with
the Biocalc program [18]. Antibody concentrations
were expressed as relative units (1 unit is the value
obtained from a 10"4 dilution of a reference serum).
Antibody titres of sera from 100 healthy blood donors
were measured, and values at least 3 s.D. higher than
the mean antibody concentration of these sera were
defined as positive.
Calculations
Sensitivity, specificity, positive predictive value,
negative predictive value, false positives and false
negatives were calculated as described by Griner et al.
[19]. A sample was designated 'true positive' if it
came from a patient with CT-SARA and antibodies
of the isotype concerned (level greater than the
mean of donor 4- 3 s.D.). A sample was designated
'true negative' if it was obtained from a patient who
had a diagnosis of RA, crystal-induced arthritis or
mechanical arthropathy and had no antibody of the
isotype concerned (level less than the mean of
donor + 3 s.D.). Thus, sensitivity = true positives/true
positives + false negatives, specificity = true negatives/
true negatives + false positives, positive predictive
value = true positives/true positives + false positives,
negative predictive value = true negatives/true neg-
atives + false negatives, false positive rate = false
positives/total patients without disease, false negative
rate = false negatives/total patients with disease.
RESULTS
Serum concentrations of antibodies against Chlamydia
The distributions obtained for IgG, IgM and IgA in
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Fio. 1.—Distribution of serum anti-Chlamydia antibody concentrations expressed in units/ml. 1. Chlamydla trachomatis sexually acquired
reactive arthritis (CT-SARA), n •» 30; 2. SARA (negative or not performed urethral/endocervical Chlamydia detection), n =- 23; 3.
undifferentiated seronegative mono/oligoarthritis, n = 56; 4. rheumatoid factor-positive rheumatoid arthritis, n = 37; 5. crystal-induced arthritis,
n = 17; 6. mechanical arthropathies, n <= 19; 7. healthy blood donors, n — 100.
the six diagnostic groups of patients and healthy blood
donors are given in Fig. 1. We observed that the groups
of patients with CT-SARA and with SARA had
the highest levels of antibodies of all isotypes
tested. They were the only groups which had positive
mean antibody concentrations (greater than the
mean + 3 S.D. of the 100 blood donors' serum values)
for all isotypes, except for the IgM of CT-SARA which
was just below the cut-off. For the group of patients
with undifferentiated mono/oligoarthritis, the means
were lower than the mean + 3 S.D. of the 100 blood
donors' serum values, but were always higher than
those obtained for the control groups. Furthermore, we
observed that with higher cut-off (greater than the
mean of the 100 blood donors' serum values + 4 S.D.
for IgG, H-6S.D. for IgM, +9 S.D. for IgA), except
for one IgA value from group 4, positive values
would be only found in the CT-SARA, SARA
and undifferentiated mono/oligoarthritis groups of
patients.
For individual or isotype combinations, the percent-
ages of samples with antibody concentration greater
than the mean + 3 S.D. of antibody concentration
obtained for donors are given in Table I. Patients
and donors with a value higher than the mean +
3 S.D. of antibody concentration obtained for donors,
TABLE I
Chlamydia-specific antibody isotype distribution in the six diagnostic groups of patients and in healthy blood donors (% of samples with values
higher than the mean of donors + 3 S.D.)
Group
IgG + IgM IgG or IgM
IgG only IgM only IgA only IgG + IgM IgG + IgA IgM + IgA + IgA or IgA
1. Chlamydia trachomatis sexually
acquired reactive arthritis (n •= 30)
2. Sexually acquired reactive arthritis
(n = 23)
3. Undifferentiated seronegative
mono/oligoarthritis (n = 56)
4. Rheumatoid arthritis (n — 37)
5. Crystal-induced arthritis (n = 17)
6. Mechanical arthropathies (n «= 19)
7. Controls (blood donors) (n - 100)
10 17
13
23
22
10 10 73
71
27
29
7
0
6
5
2
13
0
12
11
1
13
5
12
16
2
2
0
0
0
0
5
0
6
5
0
5
3
0
0
0
2
0
0
0
0
47
8
36
37
5
53
92
64
63
95
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TABLE II
Sensitivity, specificity, positive predictive value, negative predictive value, false-positive and false-negative values obtained for the different
isotypes and their combinations
Sensitivity Specificity Predictive value Predictive value False-positive False-negative
(%) (%) ( + )(%) (-)(%) rate(%) rate (%)Isotype(s) considered
IgG only
IgM only
IgA only
IgM and IgA
IgM and/or IgA
IgG and IgM
IgG and/or IgM
IgG and IgA
IgG and/or IgA
IgG and IgM and IgA
IgG and/or IgM and/or IgA
10
17
23
10
63
0
50
10
57
3
73
97
95
90
99
81
100
88
97
84
100
78
60
56
50
75
58
-
63
60
59
100
58
72
73
74
73
84
71
81
72
82
72
88
3
5
10
1
19
0
12
3
16
0
22
90
83
77
90
37
100
50
90
43
97
27
Positive patients were 30 patients from group 1 (C. trachomatis sexually acquired reactive arthritis) and negative patients were 37 patients
with rheumatoid arthritis, 17 patients with crystal-induced arthritis and 19 patients with mechanical arthropathies.
considered positive for Chlamydia antibodies, were
observed in all groups tested. The prevalence of
positive values was highest in the group of patients with
CT-SARA: 73% had at least one positive isotype. In
the group of patients with SARA, 71% had at least one
positive isotype and in the group of patients with
undifferentiated seronegative mono/oligoarthritis,
53%. In all other groups, positive patients were found
for any of the three isotypes, reaching 36% for the
group of patients with crystal-induced arthritis and
37% for the group of mechanical arthropathies. As
shown in Fig. 1, most of the positive values obtained
with groups 4-6, used as controls, were just slightly
higher than the cut-off limit.
No difference was observed between the HLA-B27-
positive and -negative patients, either for the mean
antibody concentration of the different isotypes or for
the prevalence of positive values.
Sensitivity, specificity, positive predictive value, negative
predictive value, false positives and false negatives
obtained for the different isotypes and their combinations
These values were calculated as described by Griner
et al. [19] and are presented in Table II. With two
different isotypes and their combination, the best
sensitivity (63%) was obtained when considering IgM
and/or IgA results with a specificity of 81%. The
negative predictive value was 84%.
DISCUSSION
In the current study, antibody responses against
Chlamydia were detected in sera of mainly two groups
of patients. One group is composed of patients with
definite, suspected or possible Chlamydia-related
rheumatic disease, the other of patients with well-
defined rheumatic diseases unrelated to Chlamydia.
Since it is well known that antibodies to C. trachomatis
are present in a large number of cases with no clinical
or microbiological evidence of chlamydial infection
[13, 14], it was important to examine the antibody
levels in healthy blood donors. We considered the
results obtained for a group of 100 blood donors to
provide a baseline for the positive antibody levels. In
order to improve specificity, we applied a relatively
high limit for a positive antibody level (3 S.D. above the
mean value for blood donors). In these conditions, the
percentage of individuals with positive antibody levels
in our blood donor population was 5%, a percentage
which is in agreement with previous studies [13,14]. In
our control groups with defined non-Chlamydia
rheumatic diseases (RA, crystal-induced arthritis and
mechanical arthropathies), the percentage of patients
with positive antibody levels was 22%. Therefore, these
patients have been exposed to Chlamydia at a higher
rate than our blood donor population. The exposure
to C. pneumoniae could be responsible for some of
the positive results since the proportion of normal
individuals with anti-C. pneumoniae antibodies
increases with age [20-22]. Indeed, the median ages of
the RA, crystal-induced arthritis and mechanical
arthropathy groups of patients (63, 51, 58) were higher
than that of the healthy control group (44) which was,
however, at middle distance between both groups of
patients, the median age of the CT-SARA group being
25. This points out the difficulty of getting an
age-matched control group for this type of study, since
most of the rheumatic diseases with no Chlamydia
implication, chosen for the control group of patients,
occur in elderly population.
In addition to the presence of positive anti-
Chlamydia antibody levels in the general population,
another difficulty is the absence of antibodies in some
of the patients with well-defined Chlamydia-'mvolvcd
rheumatic disease, i.e. CT-SARA. Our results showed
that 27% of these patients had no aaXi-Chlamydia
antibodies. Other authors have made similar
observations [3, 9, 23]. Several explanations could be
proposed. It is possible that antibodies are synthesized,
but bind to antigen with high affinity and are not free
for detection. It could also be hypothesized that, in
some instances, chlamydial antigens are not processed
or not presented in the context of HLA class II antigens
or not recognized by CD4+ T cells and could thus
escape immune surveillance. This absence of an
immune response could be influenced by genetic factors
of the host or by the state of the bacteria. Indeed,
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in Chlamydia-assodated reactive arthritis, atypical
chlamydial forms have been observed [24]. They appear
identical to persisting chlamydiae described in vitro,
known to have a decrease in the levels of the major
structural constituents [25].
In spite of these observations, which lower both the
sensitivity and specificity of any serological test used
for the diagnosis of Chlamydia reactive arthritis,
we determined the sensitivity, specificity, positive
predictive value and negative predictive value for each
isotype and their combination. It has been suggested
that the consideration of particular isotypes, mainly
IgM and IgA, may be diagnostically useful. As IgG
might remain in the circulation for periods in excess
of 1 yr after cessation of apparent infection [3], the
significance of raised IgG titres seems uncertain [3],
because it is difficult to differentiate between a current
or previous infection. The short duration of the IgM
antibody response should indicate a recent or current
chlamydial infection [3]. The detection of IgA indicates
prolonged B-cell stimulation by a persistent agent since
their half-life is only 5-6 days in normal subjects [26].
For our calculations, we took positive patients as
those from group 1 (CT-SARA), and negative patients
from groups 5 (RA), 6 (crystal-induced arthritis) and
7 (mechanical arthropathies). The main problem was
the low sensitivity of this type of determination
(between 0 and 73%). The specificity was always
>78%. With two different isotypes and their
combination, the best sensitivity (63%) was obtained
when considering IgM and/or IgA results, with a
specificity of 81%. The negative predictive value was
84%; therefore the absence of IgM and/or IgA could
be helpful in order to eliminate suspicion, but is not
sufficient since there would be 19% false positives and
37% false negatives. Thus, a negative serological test
would not provide reasonable evidence that subclinical
infection is not present. Our results agree with those of
Sieper et al. [16].
With a higher cut-off (greater than the mean of the
100 blood donors' serum values + 4 S.D. for IgG,
+ 6 S.D. for IgM, +9 S.D. for IgA), it was possible to
get a specificity of 100% for IgG and IgM, and of 99%
for IgA. The sensitivity was decreased slightly for IgG
and by about hah" for IgM and IgA. However, in these
conditions of analysis, most of the positive values
(except one) were found in groups of patients with
proven or possible CT-SARA. In the group of patients
with an undifferentiated mono/oligoarthritis, some
individual values were very high and suggest the
presence of Chlamydia infection in some of these
patients. High antibody titres are thus useful for
diagnosis.
To summarize, our results suggest that, in our
experimental conditions, only very high values of
specific isotypes of zntl-Chlamydia antibodies in serum
could indicate a diagnosis of Chlamydia reactive
arthritis.
It is possible that a better antigen preparation could
increase both sensitivity and specificity. Arthritogen
proteins or peptides could be used instead of
elementary or reticulate body preparations, but recent
results [27] are not promising for the determination of
these target proteins or peptides.
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